Trial Search Results

Mifepristone in Refractory Depression

The purpose of the study is to examine the effectiveness of mifepristone treatment in patients with refractory depression. Refractory depression is defined as clinical depression that is unimproved after treatment with at least 2 different antidepressants of adequate dose and time trial. Mifepristone will augment current medications.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Stanford University

Stanford Investigator(s):

Intervention(s):

  • Drug: Mifepristone
  • Drug: Placebo Oral Tablet

Phase:

N/A

Eligibility


Inclusion Criteria::

   - 21-item HAM-D score of 20 or above.

   - If currently taking antipsychotic, antidepressant, anticonvulsant, and/or
   mood-stabilizing medications, must be stable on the medication for at least three
   weeks prior to entering the study.

   - At least 2 failed antidepressant medication trials of adequate dose and duration.

   - Between 18 and 75 years of age.

   - Not currently pregnant or trying to become pregnant.

Exclusion Criteria:-History of schizophrenia or other psychotic disorders.

   - Transcranial magnetic stimulation treatment or ECT in the 3 months prior to starting
   the study.

   - History of vagus nerve stimulation treatment.

   - No unstable or untreated cardiovascular disease, hypertension, or endocrine disorder.

   - Current use of oral contraceptives or any other drug that may result in adverse
   drug-mifepristone interactions effects (including Amiodarone, Clarithromycin,
   Erythromycin, Fluconazole, Fluvoxamine, Indinavir, Intraconazole, Ketoconazole,
   Metronidazole, Miconazole, Nefazodone, Nelfinavir, Norfloxacin, Omeprazole, Quinine,
   Ritonavir, Saquinavir, Troleandomycin, Zafirlukast, Carbamazepine, Dexamethasone,
   Ethosuximide, Phenobarbital, Phenytoin, Primidone, Rifabutin, Rifampin, Troglitazone).
   A 30-day wash-out period for oral contraceptives is required before mifepristone
   begins.

   - Previous allergic reaction to mifepristone or drugs of similar chemical structure.

Ages Eligible for Study

18 Years - 75 Years

Genders Eligible for Study

All

Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Jennifer Keller
6507240070
Not Recruiting